From the Clinical to the Bench: Exploring the Insulin Modulation Effects of Tacrolimus and Belatacept
Calcineurin inhibitors (CNIs) are critical in preventing rejection posttransplantation but pose an increased risk of post-transplant diabetes (PTD). Recent studies show that late conversion from CNIs to belatacept, a costimulation blocker, improves HbA1c in kidney transplant recipients with PTD or d...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2024-04-01
|
| Series: | Cell Transplantation |
| Online Access: | https://doi.org/10.1177/09636897241246577 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850128340133871616 |
|---|---|
| author | Quentin Perrier Cécile Cottet-Rouselle Marine de-Beaumont Johan Noble Sandrine Lablanche |
| author_facet | Quentin Perrier Cécile Cottet-Rouselle Marine de-Beaumont Johan Noble Sandrine Lablanche |
| author_sort | Quentin Perrier |
| collection | DOAJ |
| description | Calcineurin inhibitors (CNIs) are critical in preventing rejection posttransplantation but pose an increased risk of post-transplant diabetes (PTD). Recent studies show that late conversion from CNIs to belatacept, a costimulation blocker, improves HbA1c in kidney transplant recipients with PTD or de novo diabetes. This study investigates whether the observed effects on PTD stem solely from CNI withdrawal or if belatacept influences PTD independently. The study assessed the impact of tacrolimus and belatacept on insulin secretion in MIN6 cells (a beta cell line) and rat islets. Tacrolimus and belatacept were administered to the cells and islets, followed by assessments of cell viability and insulin secretion. Tacrolimus impaired insulin secretion without affecting cell viability, while belatacept showed no detrimental effects on either parameter. These findings support clinical observations of improved HbA1c upon switching from tacrolimus to belatacept. Belatacept holds promise in islet or pancreas transplantation, particularly in patients with unstable diabetes. Successful cases of islet transplantation treated with belatacept without severe hypoglycemia highlight its potential in managing PTD. Further research is needed to fully understand the metabolic changes accompanying the transition from CNIs to belatacept. Preserving insulin secretion emerges as a promising avenue for investigation in this context. |
| format | Article |
| id | doaj-art-8cb25900abfc4591bcf1bb12eb04518f |
| institution | OA Journals |
| issn | 1555-3892 |
| language | English |
| publishDate | 2024-04-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Cell Transplantation |
| spelling | doaj-art-8cb25900abfc4591bcf1bb12eb04518f2025-08-20T02:33:20ZengSAGE PublishingCell Transplantation1555-38922024-04-013310.1177/09636897241246577From the Clinical to the Bench: Exploring the Insulin Modulation Effects of Tacrolimus and BelataceptQuentin Perrier0Cécile Cottet-Rouselle1Marine de-Beaumont2Johan Noble3Sandrine Lablanche4Grenoble Alpes University, INSERM U1055, LBFA, Pharmacy Department, Grenoble Alpes University Hospital, Grenoble, FranceGrenoble Alpes University, INSERM U1055, LBFA, Grenoble, FranceGrenoble Alpes University, INSERM U1055, LBFA, Grenoble, FranceGrenoble Alpes University, INSERM, IAB, Nephrology, Hemodialysis, Apheresis and Kidney Transplantation Department, Grenoble Alpes University Hospital, Grenoble, FranceGrenoble Alpes University, INSERM U1055, LBFA, Diabetology and Endocrinology Department, Grenoble Alpes University Hospital, Grenoble, FranceCalcineurin inhibitors (CNIs) are critical in preventing rejection posttransplantation but pose an increased risk of post-transplant diabetes (PTD). Recent studies show that late conversion from CNIs to belatacept, a costimulation blocker, improves HbA1c in kidney transplant recipients with PTD or de novo diabetes. This study investigates whether the observed effects on PTD stem solely from CNI withdrawal or if belatacept influences PTD independently. The study assessed the impact of tacrolimus and belatacept on insulin secretion in MIN6 cells (a beta cell line) and rat islets. Tacrolimus and belatacept were administered to the cells and islets, followed by assessments of cell viability and insulin secretion. Tacrolimus impaired insulin secretion without affecting cell viability, while belatacept showed no detrimental effects on either parameter. These findings support clinical observations of improved HbA1c upon switching from tacrolimus to belatacept. Belatacept holds promise in islet or pancreas transplantation, particularly in patients with unstable diabetes. Successful cases of islet transplantation treated with belatacept without severe hypoglycemia highlight its potential in managing PTD. Further research is needed to fully understand the metabolic changes accompanying the transition from CNIs to belatacept. Preserving insulin secretion emerges as a promising avenue for investigation in this context.https://doi.org/10.1177/09636897241246577 |
| spellingShingle | Quentin Perrier Cécile Cottet-Rouselle Marine de-Beaumont Johan Noble Sandrine Lablanche From the Clinical to the Bench: Exploring the Insulin Modulation Effects of Tacrolimus and Belatacept Cell Transplantation |
| title | From the Clinical to the Bench: Exploring the Insulin Modulation Effects of Tacrolimus and Belatacept |
| title_full | From the Clinical to the Bench: Exploring the Insulin Modulation Effects of Tacrolimus and Belatacept |
| title_fullStr | From the Clinical to the Bench: Exploring the Insulin Modulation Effects of Tacrolimus and Belatacept |
| title_full_unstemmed | From the Clinical to the Bench: Exploring the Insulin Modulation Effects of Tacrolimus and Belatacept |
| title_short | From the Clinical to the Bench: Exploring the Insulin Modulation Effects of Tacrolimus and Belatacept |
| title_sort | from the clinical to the bench exploring the insulin modulation effects of tacrolimus and belatacept |
| url | https://doi.org/10.1177/09636897241246577 |
| work_keys_str_mv | AT quentinperrier fromtheclinicaltothebenchexploringtheinsulinmodulationeffectsoftacrolimusandbelatacept AT cecilecottetrouselle fromtheclinicaltothebenchexploringtheinsulinmodulationeffectsoftacrolimusandbelatacept AT marinedebeaumont fromtheclinicaltothebenchexploringtheinsulinmodulationeffectsoftacrolimusandbelatacept AT johannoble fromtheclinicaltothebenchexploringtheinsulinmodulationeffectsoftacrolimusandbelatacept AT sandrinelablanche fromtheclinicaltothebenchexploringtheinsulinmodulationeffectsoftacrolimusandbelatacept |